Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Bruce Campbell (2) and Stockchase Discover commented about whether PYPL-Q, CAE-T, VMD-T, JUSHF-OTC, SGMD-X, CTS-T, XBC-T, CMC-X, BTE-T, WELL-T, JWEL-T, GSY-T, NDVA-X, RHT-X, GRN-T, FUEL-CN, DNTL-T, MG-T, TGIF-CN, EMPS-CSE, AVN-X, SIS-T are stocks to buy or sell.
- Page 3/4
- Next Page
WATCH
They had more challenges then Greenlane Renewables and their market cap was at once much larger than GR's. Shares have fallen further than GR. The sector has a tailwind, though, for the next decade. See if XBC delivers a couple of strong quarters. Wait to see if XBC operates better. There is a lot of runway ahead, though.
INDUSTRIAL PRODUCTS
TOP PICK
They move small/mid-sized businesses into the cloud. Since 2017, they've been growing organically and by 30 acquisitions. They cross-sell and increase the customer base. They are expanding into Europe, most recently buying a company in the UK. Compounded EBITDA growth is 70% and revenue growth is around 50% compounded over the last 3 years. It trades at only 5.5x 2023's EBITDA vs. peers of 8.5-10.5x. He recently re-entered the stock. (Analysts’ price target is $10.31)
Technology
BUY
A headwind is that it's a small-cap which the market is not buying now. Management team has a great track record. From June 2021, they've grown the company from $10 million of annual run rate revenue to $90 million (after some acquisitions). More acquisitions and organic growth lie ahead. They're profitable. It's his largest position. He sees shares going much higher.
Healthcare
TOP PICK
Interesting operators including Wall Street, tech and cannabis expertise. Altogether they can grow organically and by acquisition. They operate in 7 states. The Safe Act has a realistic chance of getting past in the U.S. which would be a boon. If not, JUSHF can continue to grow by buying. They're disciplined and focused in specific places where they operate. (Analysts’ price target is $4.99)
agriculture
BUY
Their ventilator business has grown in recent years tough they struggled to access Covid patients in hospitals. They had great revenues in their last quarter. They're expanding operations as they enter new markets. EBITDA was lower than expected, so shares pulled back. They trade at half the PE of their peers. The CEO is one of the biggest shareholders. (Analysts’ price target is $15.86)
0
BUY ON WEAKNESS
Allan Tong’s Discover Picks CAE has some things going for it. Fingers crossed, the Covid pandemic looks like it is truly behind us. There's been a boom in travel that shows no sign of abating. Airlines need pilots. Period. Given geopolitical tensions triggered by Russia, defence budgets are on the rise, and certainly not shrinking. Expect defence dollars to trickle onto CAE's bottom line. Also, the company's order backlog jumped 26% between Q1-2022 and Q1-2023, amounting to over $10.026 billion.
Caveats: A recession could slow down business, but demand from defence could buffer that. Also, CAE trades at a high beta of 1.93. Read 2 Stocks on Sale: CAE and Paypal for our full analysis.
transportation equip & components
BUY ON WEAKNESS
Allan Tong’s Discover Picks The sum result? PayPal sales slowed and the company lowered its revenue forecasts last November, January and April. In Q2, PayPal posted its first net loss since 2014, despite net revenue growing 9% year-over-year. In August 2021, PayPal shares scaled $288. Now, it's trading below its 50-day moving average of $91.43. Accordingly, PayPal's PE has fallen from 68x from that $288 high to 54x though it tumbled below 25x last June.
Has PayPal hit bottom?
It might have already. The stock dipped below $70 twice over the summer (June 30 and July 14) then touched $100 for a few days during the bear market rally of mid-August. As I write, PayPal is hovering below $90, dragged down along with the rest of the market. Read 2 Stocks on Sale: CAE and Paypal for our full analysis.
0
BUY
As a 5-year hold Current growth estimates are 12% and 13% sales growth and 68% gross margins. 10% of their market cap is cash. There's a gap between between expectations between now and 2023. The price target is $143 based on 48 buys and three holds and no sells. Sentiment hasn't changed yet. Buy it in the $80s and hold for 5 years.
Technology
